Linda Armstrong Net Worth

Linda Armstrong biography

Dr. Linda Washington Armstrong M.D. serves as Independent Director of the Company. Dr. Armstrong was appointed as a member of the Board in October 2020 and serves on the newly formed Science and Technology Committee of the Board. Dr. Armstrong is an accomplished biopharmaceutical executive with more than 20 years of experience in respiratory diseases and therapeutics. Since 2016, she has served as the Global Head of the Respiratory Development Unit at Novartis (SWX:NOVN), where she is responsible for the development of therapies to treat patients with respiratory and allergic conditions. Dr. Armstrong served in a variety of roles at Novartis since 2007, including the Head of Clinical Development & Medical Affairs, Cell and Gene Therapy and Global Head of Patient Safety. Prior to joining Novartis between 2001-2007, she served as Medical Safety Director and subsequently as Senior Director, Medical Affairs at Pfizer, Inc. (NYSE:PFE). Dr. Armstrong also served as Group Director, Respiratory Diseases at the Schering Plough Research Institute. As a Board-Certified Pulmonologist and Internist, Dr. Armstrong served on the faculty of New York University Medical Center prior to joining Schering-Plough. She received her medical degree from Yale University School of Medicine, New Haven, Connecticut and her Bachelor’s Degree from Harvard University, Cambridge, Massachusetts. The Company believes Dr. Armstrong’s experience and knowledge as a medical professional and her experience in various leadership roles in successful pharmaceutical companies and biologics will be a valuable addition to the Board and the Company.

How old is Linda Armstrong?

Linda Armstrong is 57, he's been the Independent Director of iBio Inc since 2020. There are 10 older and 5 younger executives at iBio Inc. The oldest executive at iBio Inc is Seymour Flug, 84, who is the Independent Director.

What's Linda Armstrong's mailing address?

Linda's mailing address filed with the SEC is C/O IBIO, INC., 8800 HSC PARKWAY, BRYAN, TX, 77807.

Insiders trading at iBio Inc

Over the last 14 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis, and William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.

What does iBio Inc do?

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.

iBio Inc executives and stock owners

iBio Inc executives and other stock owners filed with the SEC include:

• Thomas Isett,
  Chairman of the Board, Chief Executive Officer
• Thomas F. Isett III,
  CEO, Pres & Chairman
• Robert Kay,
  Interim Secretary, Interim Treasurer, Director
• Randy Joe Maddux,
  Chief Operating Officer
• Dr. Martin B. Brenner D.V.M., Ph.D.,
  Chief Scientific Officer
• Robert Erwin,
  President
• Robert B. Kay,
  Interim Sec. & Interim Treasurer
• James Hill,
  Independent Director
• John McKey,
  Independent Director
• Seymour Flug,
  Independent Director
• Glenn Chang,
  Independent Director
• Stephen Kilmer,
  Investor Relations
• Gary Sender,
  Independent Director
• Alexandra Kropotova,
  Independent Director
• Linda Armstrong,
  Independent Director
• John Delta,
  Principal Financial Officer, Principal Accounting Officer
• Carlos Picosse,
  Chief Exec. Officer of IBio Brazil
• Dr. Melissa Berquist Ph.D.,
  VP and Head of Vaccines & Animal Health
• Lisa Middlebrook,
  Chief HR Officer
• Robert Matthew Lutz,
  Chief Financial & Bus. Officer
• Mark A Giannone,
  Chief Financial Officer
• Kenneth Bryan Dart,
  10% owner
• Carl Desantis,
  10% owner
• Philip K. Russell,
  Director
• Arthur Y Elliott,
  Director
• Capital Ltd Portfolio Servi...,
  
• Ryan E Terence,
  Chief Scientific Officer
• Randy Joe Maddux,
  Chief Operating Officer
• Robert Matthew Lutz,
  See Remarks
• James P. Mullaney,
  Chief Financial Officer
• Evert B. Schimmelpennink,
  Director
• E Gerald Kay,
  10% owner
• Jules A. Musing,
  Director
• William D Clark,
  Director
• Martin Brenner,
  See Remarks
• Felipe Duran,
  Chief Financial Officer